The refinancing provides immediate financial benefits through lower interest rates and an extended maturity profile. The availability of the delayed draw term loan offers strategic flexibility for future acquisitions or debt refinancing, particularly for the 2028 Senior Notes. Traders should monitor the company's use of the delayed draw facility and any potential impact on its credit ratings.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $12.32entry
- T+1 · 7mo ago +3.65%α +2.44% · $12.77
- T+5 · 7mo ago +2.84%α −0.45% · $12.67
- T+20 · 6mo ago −8.77%α −16.49% · $11.24
- T+60 · 4mo ago −18.91%α −27.84% · $9.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AdaptHealth refinanced its senior secured credit facility, terminating its prior credit agreement and establishing a new $1.1 billion facility. The new facility includes a $325 million term loan used to repay existing debt, a $450 million revolving credit line, and a $325 million delayed draw term loan for future use, primarily to refinance 2028 Senior Notes. The transaction extends debt maturity, reduces borrowing costs, and enhances financial flexibility.
Key Financial Metrics
Key Facts
- Entered into a new $1.1 billion senior secured credit facility on April 10, 2026.
- Terminated the prior credit agreement by repaying all outstanding debt.
- New facility includes $325 million Term Loan A, $450 million revolving commitment, and $325 million delayed draw term loan.
- Proceeds from the initial term loan were used to repay existing debt under the prior credit agreement.
- Delayed draw term loan can be used to refinance 2028 Senior Notes and for permitted acquisitions.
- The new facility extends maturity to April 2031 and reduces the cost of debt, with the lowest pricing tier reduced from 1.50% to 1.125% over SOFR.
- The transaction was supported by recent credit rating upgrades from S&P and Moody's.
Financial Impact
The new $1.1 billion facility replaces the prior debt, with $325 million used immediately to repay existing debt and $325 million available for future use to refinance 2028 Senior Notes. The weighted average cost of debt is expected to decrease by at least 25bps.
Risk Factors
- The delayed draw term loan is available for up to two years, creating a potential overhang if not used.
- The company's ability to maintain its improved credit profile is critical to sustaining the lower borrowing costs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024835 |
| Document: adapthealth-8xkboafacility.htm | 0001628280-26-024835 |
| Document: ahcopressrelease-carefixap.htm | 0001628280-26-024835 |
| Document: 0001628280-26-024835-index-headers.html | 0001628280-26-024835 |
| Document: 0001628280-26-024835-index.html | 0001628280-26-024835 |
| Document: 0001628280-26-024835.txt | 0001628280-26-024835 |
Track record
20 reports on AHCO
5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +47.49% at T+60 after the Jul 2, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.80 Now $7.73 −0.90% settles Nov 18
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $7.89 Now $7.73 −2.03% settles Nov 17
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $7.87 to $7.66 Now $7.73 −1.78% ▼ −2.67% −2.31% vs SPY
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $7.35 to $7.72 Now $7.73 +5.17% ▲ +5.03% +5.40% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $7.35 to $7.72 Now $7.73 +5.17% ▲ +5.03% +5.40% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $7.33 to $7.35 Now $7.73 +5.46% ▲ +0.27% −2.09% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $7.41 to $7.33 Now $7.73 +4.32% ▼ −1.08% −1.39% vs SPY
- Nov 3, 202613d ago 8-K Mixed 6/10 Entry $6.28 to $7.31 Now $7.73 +23.09% ▲ +16.40% +14.75% vs SPY
- Oct 29, 202619d ago Court Ruling Neutral 2/10 Entry $5.81 to $5.91 Now $7.73 +33.05% ▲ +1.72% +2.20% vs SPY
- Oct 13, 20264w ago SC 13G/A Bearish 4/10 Entry $6.33 to $6.25 Now $7.73 −22.12% ▲ +1.26% +0.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers